← back to search

Kenta Masui

University of Nagasaki · JP
Area of research
Genetics · Molecular Biology
Research interest
Research interests include Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, Epigenetics and DNA Methylation, and PI3K/AKT/mTOR signaling in cancer.
h-index
30
citations
4,821
works
141
NIH funding
primary concept
email

Recent publications

Dual Regulation of Histone Methylation by mTOR Complexes Controls Glioblastoma Tumor Cell Growth via EZH2 and SAM
Molecular Cancer Research 2020cited by 55position: middledoi
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Nature reviews. Cancer 2019cited by 374position: middledoi
mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT
Molecular Cell 2017cited by 206position: middledoi
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Cancer Cell 2016cited by 329position: middledoi
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Cancer Cell 2016cited by 167position: middledoi
Molecular classification of gliomas
Handbook of clinical neurology 2016cited by 113position: firstdoi
Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance
Proceedings of the National Academy of Sciences 2015cited by 118position: firstdoi
mTORC2 in the center of cancer metabolic reprogramming
Trends in Endocrinology and Metabolism 2014cited by 125position: firstdoi
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Science 2013cited by 684position: middledoi
mTOR Complex 2 Controls Glycolytic Metabolism in Glioblastoma through FoxO Acetylation and Upregulation of c-Myc
Cell Metabolism 2013cited by 397position: firstdoi
EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer
Cell Metabolism 2013cited by 163position: middledoi
A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
Carcinogenesis 2013cited by 108position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Paul S. Mischel · Stanford Health Care11 papers (2013–2020)Webster K. Cavenee · University of California San Diego8 papers (2013–2020)Timothy F. Cloughesy · UCLA Medical Center6 papers (2013–2017)Beatrice Gini · University of California, San Francisco6 papers (2013–2017)Genaro R. Villa · Brigham and Women's Hospital4 papers (2013–2017)Yuchao Gu · Qingdao University of Science and Technology4 papers (2013–2017)Kazuhiro Tanaka · Kobe University3 papers (2013–2015)Shaojun Zhu · Chinese Academy of Sciences3 papers (2013–2013)Huijun Yang · Peking University Shenzhen Hospital3 papers (2013–2017)Shiro Ikegami · Chiba University3 papers (2015–2017)William H. Yong · University of California, Irvine3 papers (2013–2015)Stanley F. Nelson · University of California, Los Angeles2 papers (2013–2013)Junfeng Bi · Fudan University2 papers (2017–2019)Huijun Yang · Chongqing University of Posts and Telecommunications2 papers (2013–2016)C. David James · Northwestern University2 papers (2013–2016)David A. Nathanson · La Jolla Bioengineering Institute2 papers (2013–2013)Tomoo Matsutani · Chiba University2 papers (2013–2016)Ivan Babić · BioMarin (United States)2 papers (2013–2013)Kiwook Hwang · California Institute of Technology2 papers (2013–2016)Heather R. Christofk · APLA Health2 papers (2013–2017)